scholarly journals Cost-effectiveness of oxaliplatin and capecitabine in the adjuvant treatment of stage III colon cancer

2006 ◽  
Vol 95 (9) ◽  
pp. 1195-1201 ◽  
Author(s):  
S Eggington ◽  
P Tappenden ◽  
A Pandor ◽  
S Paisley ◽  
M Saunders ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Cost Effectiveness ◽  
Adjuvant Treatment ◽  
Stage Iii ◽  
Stage Iii Colon Cancer

Cost-effectiveness analysis of oxaliplatin/5-FU/LV in adjuvant treatment of stage III colon cancer in the U.S

2005 ◽  
Vol 23 (16_suppl) ◽  
pp. 3532-3532 ◽  
Author(s):  
S. Aballea ◽  
J. Chancellor ◽  
M. Raikou ◽  
M. Drummond ◽  
M. Weinstein ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Cost Effectiveness ◽  
Adjuvant Treatment ◽  
Cost Effectiveness Analysis ◽  
Stage Iii ◽  
Stage Iii Colon Cancer ◽  
Effectiveness Analysis ◽  
The U.S

Cost-effectiveness of adjuvant capecitabine, Mayo Clinic and de Gramont regimens for stage III colon cancer in the French setting

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 13506-13506
Author(s):  
P. R. Dufour ◽  
J. Douillard ◽  
M. Ychou ◽  
J. Seitz ◽  
G. Perrocheau ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Clinical Trials ◽  
Cost Effectiveness ◽  
Adjuvant Treatment ◽  
Mayo Clinic ◽  
Stage Iii ◽  
Sensitivity Analyses ◽  
Base Case ◽  
Stage Iii Colon Cancer ◽  
The Cost

13506 Background: The oral fluoropyrimidine capecitabine is as effective but better tolerated than i.v. 5-FU/LV as first-line treatment in patients (pts) with metastatic colorectal cancer. Costs associated with the administration route could vary widely according to national rules and medical practice. We compared costs and outcomes of capecitabine, the Mayo Clinic, and de Gramont regimens as adjuvant treatment for stage III colon cancer. Methods: We assessed the cost-effectiveness of the three regimens using the third-party payer perspective, time horizon and efficacy/safety data (adjusted for indirect comparisons) from two published clinical trials [Twelves et al. N Engl J Med 2005; Andre et al. J Clin Oncol 2003]. The costs of chemotherapy and the treatment of side effects were estimated from the clinical trials and expert opinion. We applied French standard costs to resources consumed and evaluated cost-effectiveness using relapse-free survival (RFS), defined in X-ACT study, as an efficacy indicator. One-way sensitivity analyses were performed varying the cost estimates for each treatment. Results: Capecitabine-treated pts had a mean life duration increase without treatment failure of 1.3 months vs. Mayo (see table). De Gramont was considered as effective as Mayo. In the base-case analysis capecitabine appeared to be dominant, more effective and less costly than either Mayo Clinic or de Gramont. In the sensitivity analyses, capecitabine remained dominant except for the minimum costs scenario vs. de Gramont. In this case, the cost-effectiveness ratio was estimated at 8997.55€ per year without relapse. Conclusions: As adjuvant treatment for colon cancer, capecitabine decreases medical resources consumed, mainly in hospitals. Its approval in this setting is expected to bring cost savings and better outcomes. [Table: see text] [Table: see text]

scholarly journals Cost-effectiveness analysis of oxaliplatin compared with 5-fluorouracil/leucovorin in adjuvant treatment of stage III colon cancer in the US

Cancer ◽  
2007 ◽  
Vol 109 (6) ◽  
pp. 1082-1089 ◽  
Author(s):  
Samuel Aballéa ◽  
Jeremy V.M. Chancellor ◽  
Maria Raikou ◽  
Michael F. Drummond ◽  
Milton C. Weinstein ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Cost Effectiveness ◽  
Adjuvant Treatment ◽  
Cost Effectiveness Analysis ◽  
Stage Iii ◽  
Stage Iii Colon Cancer ◽  
Effectiveness Analysis ◽  
The Us

Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer

2017 ◽  
Author(s):  
Kelly McLeon
Keyword(s):  
Colon Cancer ◽  
Adjuvant Treatment ◽  
Disease Free Survival ◽  
Stage Iii ◽  
Reference Standard ◽  
Free Survival ◽  
Stage Iii Colon Cancer ◽  
Study Intervention ◽  
Disease Free

The landmark MOSAIC trial examined whether the addition of oxaliplatin to a postoperative adjuvant treatment regimen of fluorouracil and leucovorin affected disease-free survival from colon cancer. The MOSAIC trial established the efficacy of FOLFOX over 5-FU/LV as adjuvant treatment for stage III colon cancer and established FOLFOX4 as the reference standard for adjuvant treatment for stage III disease. This chapter describes the basics of the study, including funding, year study began, year study was published, study location, who was studied, who was excluded, how many patients, study design, study intervention, follow-up, endpoints, results, and criticism and limitations. The chapter briefly reviews other relevant studies and information, gives a summary and discusses implications, and concludes with a relevant clinical case.

Sign in / Sign up

Export Citation Format

Share Document